Trial Profile
A Phase I/II Trial Of Very Low to Low-Doses of Continuous Azacitidine in Combination With Standard Doses of Lenalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2020 Status changed from active, no longer recruiting to completed.
- 09 May 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
- 09 May 2016 Status changed from recruiting to active, no longer recruiting.